company background image

Aurora Spine TSXV:ASG Stock Report

Last Price


Market Cap







21 May, 2022


Company Financials
ASG fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

ASG Stock Overview

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada.

Aurora Spine Competitors













Price History & Performance

Summary of all time highs, changes and price drops for Aurora Spine
Historical stock prices
Current Share PriceCA$0.40
52 Week HighCA$0.80
52 Week LowCA$0.22
1 Month Change-5.95%
3 Month Change64.58%
1 Year Change-49.36%
3 Year Change9.72%
5 Year Change139.39%
Change since IPO-70.74%

Recent News & Updates

May 04
Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

ASGCA Medical EquipmentCA Market

Return vs Industry: ASG underperformed the Canadian Medical Equipment industry which returned -39.3% over the past year.

Return vs Market: ASG underperformed the Canadian Market which returned 4.8% over the past year.

Price Volatility

Is ASG's price volatile compared to industry and market?
ASG volatility
ASG Average Weekly Movement16.3%
Medical Equipment Industry Average Movement13.0%
Market Average Movement9.9%
10% most volatile stocks in CA Market16.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: ASG is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ASG's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

2013n/aTrent Northcutt

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures.

Aurora Spine Fundamentals Summary

How do Aurora Spine's earnings and revenue compare to its market cap?
ASG fundamental statistics
Market CapUS$20.53m
Earnings (TTM)-US$2.36m
Revenue (TTM)US$10.54m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ASG income statement (TTM)
Cost of RevenueUS$5.71m
Gross ProfitUS$4.83m
Other ExpensesUS$7.19m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date


Earnings per share (EPS)-0.035
Gross Margin45.84%
Net Profit Margin-22.37%
Debt/Equity Ratio41.0%

How did ASG perform over the long term?

See historical performance and comparison


Is Aurora Spine undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ASG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ASG's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: ASG is unprofitable, so we can't compare its PE Ratio to the North American Medical Equipment industry average.

PE vs Market: ASG is unprofitable, so we can't compare its PE Ratio to the Canadian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ASG's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ASG is good value based on its PB Ratio (3.7x) compared to the CA Medical Equipment industry average (4.7x).

Future Growth

How is Aurora Spine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aurora Spine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Aurora Spine performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ASG is currently unprofitable.

Growing Profit Margin: ASG is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ASG is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare ASG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).

Return on Equity

High ROE: ASG has a negative Return on Equity (-42.36%), as it is currently unprofitable.

Financial Health

How is Aurora Spine's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ASG's short term assets ($8.4M) exceed its short term liabilities ($2.6M).

Long Term Liabilities: ASG's short term assets ($8.4M) exceed its long term liabilities ($2.4M).

Debt to Equity History and Analysis

Debt Level: ASG has more cash than its total debt.

Reducing Debt: ASG's debt to equity ratio has increased from 33.9% to 41% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ASG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ASG has less than a year of cash runway if free cash flow continues to grow at historical rates of 21.4% each year.


What is Aurora Spine current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ASG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ASG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ASG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASG's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ASG has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Trent Northcutt (54 yo)





Mr. Trent J. Northcutt is the Chief Executive Officer and President at Aurora Spine Corporation since February 2012. He is a Founder of Aurora Spine Corporation. Mr. Northcutt served as Vice President at S...

CEO Compensation Analysis

Compensation vs Market: Trent's total compensation ($USD143.04K) is about average for companies of similar size in the Canadian market ($USD168.24K).

Compensation vs Earnings: Trent's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: ASG's management team is seasoned and experienced (9.3 years average tenure).

Board Members

Experienced Board: ASG's board of directors are considered experienced (8.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ASG insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.

Top Shareholders

Company Information

Aurora Spine Corporation's employee growth, exchange listings and data sources

Key Information

  • Name: Aurora Spine Corporation
  • Ticker: ASG
  • Exchange: TSXV
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: CA$26.359m
  • Shares outstanding: 66.73m
  • Website:


  • Aurora Spine Corporation
  • 20 Holly Street
  • Suite 300
  • Toronto
  • Ontario
  • M4S 3B1
  • Canada


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.